Gastric Cancer - Pipeline Insight, 2021
This report can be delivered to the clients within 7-10 Business Days
DelveInsight’s, “Gastric Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Gastric Cancer: Overview
Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It’s also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. Many stomach cancers are linked to lifestyle or environmental factors, including diet. Stomach cancer is linked with a bacteria that lives in the stomach called Helicobacter pylori. But not everyone with Helicobacter pylori will develop stomach cancer. The most common symptoms of stomach cancer include: difficulty swallowing (dysphagia), weight loss, indigestion (dyspepsia) that doesn't go away, feeling full after eating small amounts, feeling or being sick, and tiredness due to low red blood cells (anaemia). There are different types of treatment for patients with gastric cancer. Seven types of standard treatment are used: Surgery, Endoscopic mucosal resection, Chemotherapy, Radiation therapy, Chemoradiation, Targeted therapy, and Immunotherapy.
'Gastric Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastric Cancer pipeline landscape is provided which includes the disease overview and Gastric Cancer treatment guidelines. The assessment part of the report embraces, in depth Gastric Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gastric Cancer Emerging Drugs
Further product details are provided in the report……..
Gastric Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Gastric Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Gastric Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastric Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastric Cancer drugs.
Gastric Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Gastric Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Gastric Cancer: Overview
Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It’s also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. Many stomach cancers are linked to lifestyle or environmental factors, including diet. Stomach cancer is linked with a bacteria that lives in the stomach called Helicobacter pylori. But not everyone with Helicobacter pylori will develop stomach cancer. The most common symptoms of stomach cancer include: difficulty swallowing (dysphagia), weight loss, indigestion (dyspepsia) that doesn't go away, feeling full after eating small amounts, feeling or being sick, and tiredness due to low red blood cells (anaemia). There are different types of treatment for patients with gastric cancer. Seven types of standard treatment are used: Surgery, Endoscopic mucosal resection, Chemotherapy, Radiation therapy, Chemoradiation, Targeted therapy, and Immunotherapy.
'Gastric Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastric Cancer pipeline landscape is provided which includes the disease overview and Gastric Cancer treatment guidelines. The assessment part of the report embraces, in depth Gastric Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Gastric Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Gastric Cancer.
This segment of the Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gastric Cancer Emerging Drugs
- IBI308: Innovent Biologics
- HLX10: Henlix Biotech
- Pamiparib: BeiGene
Further product details are provided in the report……..
Gastric Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Gastric Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Gastric Cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Gastric Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastric Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastric Cancer drugs.
Gastric Cancer Report Insights
- Gastric Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gastric Cancer drugs?
- How many Gastric Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastric Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastric Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gastric Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Innovent Biologics
- Henlix Biotech
- BeiGene
- Hanmi Pharmaceutical Company Limited
- Hutchison Medipharma Limited
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Russian Pharmaceutical Technologies
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Idience
- AnewPharma
- MedPacto, Inc.
- Five Prime Therapeutics, Inc.
- Genentech
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Cellid Co., Ltd.
- Nanjing Legend Biotech Co.
- Eisai
- Jiangsu Hengrui Medicine Co.
- SYZ Cell Therapy Co.
- LintonPharm Co.,Ltd.
- Macrogenics
- OncoTherapy Science
- Avid Bioservices
- Taizhou EOC Pharma Co., Ltd.
- Bristol-Myers Squibb
- Carsgen Therapeutics, Ltd.
- Chengdu Kanghong Biotech Co., Ltd.
- Ganymed Pharmaceuticals
- Merck Sharp & Dohme Corp.
- NextCure, Inc.
- AstraZeneca
- Pfizer
- Pieris Pharmaceuticals, Inc.
- Ambrx, Inc.
- Merus N.V.
- GeneQuantum Healthcare (Suzhou) Co., Ltd.
- Highlight Therapeutics
- Qilu Pharmaceutical Co., Ltd.
- Green Cross Corporation
- Imugene Limited
- Vedanta Biosciences, Inc.
- Acepodia Biotech Inc.
- Keymed Biosciences Co.Ltd
- Bold Therapeutics, Inc.
- Regeneron Pharmaceuticals
- Celon Pharma SA
- Inhibrx, Inc.
- HiberCell, Inc.
- Treos Bio
- IBI308
- HLX10
- Pamiparib
- FLX475
- Volitinib
- IBI-310
- Anlotinib
- Alofanib
- DP303c
- IDX-1197
- HLX22
- CM082
- TEW-7197
- Bemarituzumab
- Atezolizumab
- KN026
- BVAC-B
- LCAR-C18S
- Lenvatinib
- SHR6390
- Camrelizumab
- MASCT-I
- Catumaxomab
- INCMGA00012
- OTSGC-A24
- Bavituximab
- Telatinib
- BMS-986213
- AB011
- KH903
- Zolbetuximab
- Epacadostat
- NC410
- Durvalumab
- Crizotinib
- PRS-343
- ARX788
- MCLA-129
- GQ1001
- BO-112
- QL1604
- GC1118
- IMU-131
- VE800
- ACE1702
- CMG901
- BOLD-100
- 89Zr?DFO?REGN3504
- CPL304110
- INBRX-106
- HC-5404-FU
- PolyPEPI 1311
Introduction
Executive Summary
Gastric Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
IBI308: Innovent Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Pamiparib: BeiGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
HC 5404 FU: HiberCell
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
PolyPEPI 1311: Treos Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Gastric Cancer Key Companies
Gastric Cancer Key Products
Gastric Cancer- Unmet Needs
Gastric Cancer- Market Drivers and Barriers
Gastric Cancer- Future Perspectives and Conclusion
Gastric Cancer Analyst Views
Gastric Cancer Key Companies
Appendix
Executive Summary
Gastric Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
IBI308: Innovent Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Pamiparib: BeiGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
HC 5404 FU: HiberCell
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
PolyPEPI 1311: Treos Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Gastric Cancer Key Companies
Gastric Cancer Key Products
Gastric Cancer- Unmet Needs
Gastric Cancer- Market Drivers and Barriers
Gastric Cancer- Future Perspectives and Conclusion
Gastric Cancer Analyst Views
Gastric Cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Gastric Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Gastric Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Gastric Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Gastric Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
